Imunon Inc
imunon.comWhat Do They Do?
Develops non-viral DNA immunotherapies for cancer and vaccine candidates for infectious diseases, including a treatment candidate for ovarian cancer.
10-K for FY2025, filed Mar 31, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 11, 2026
−$2.8MView ↗
- ▲ +3% (Loss)
- vs −$2.7M in Q2 FY2025
-
Jun 30, 2026
Interim CFO retires and a new interim CFO is appointed
Jeffrey Church retired from the interim CFO role, and Josh Blacher became interim CFO.
Sources
8-K, filed Jun 30, 2026
On June 29, 2026, Jeffrey Church informed Imunon, Inc. (the “Company”) of his intent to retire from the position of interim Chief Financial…View ↗
Who Do They Compete With?
Competes with Sanofi-Aventis, GlaxoSmithKline, Merck, Pfizer, and AstraZeneca
10-K for FY2025, filed Mar 31, 2026We face and will continue to encounter competition with an array of existing or development-stage drug approaches targeting diseases we are…View ↗
Loading...
